8-K: FONAR Corporation Receives Non-Binding Take-Private Proposal from CEO-Led Group

FONAR Corporation announced the receipt of a preliminary, non-binding proposal from a group led by its CEO, Timothy Damadian, to acquire all outstanding capital stock not currently owned by the group at a premium of at least 10%.

Summary

• FONAR Corporation received a preliminary, non-binding proposal letter dated July 7, 2025, from a Proposed Acquisition Group.
• The Proposed Acquisition Group is led by Timothy Damadian, the company's Chief Executive Officer, and includes certain members of the management team, Board of Directors, and third parties.
• The proposal aims to acquire all of FONAR's outstanding capital stock not currently owned by the Proposed Acquisition Group.
• The anticipated price per share is a premium of no less than 10% to the average closing market price of FONAR's common stock for the 90 trading days immediately preceding July 1, 2025.
• The Proposed Acquisition Group currently beneficially owns approximately 5.01% of the outstanding FONAR stock.
• FONAR's Board of Directors has established a special committee, composed of independent and disinterested directors, to carefully review the proposal.
• Shareholders are advised that no action is required from them at this time.
• The proposal is an indication of interest and does not constitute a binding commitment, with no assurance that the transaction will be pursued, approved, or consummated.

Sentiment

Score: 6

Explanation: The proposal offers a premium to shareholders and indicates potential value realization, which is positive. However, the non-binding nature and lack of assurance regarding consummation introduce significant uncertainty and risk, preventing a higher score. The company's historical innovation and unique product offering are positive underlying factors.

Positives

• The proposal offers a premium of no less than 10% over the 90-day average closing market price, potentially providing a favorable return for existing shareholders.
• A special committee consisting of independent and disinterested directors has been established to ensure an objective review of the proposal, aiming to protect the best interests of the company and all shareholders.

Negatives

• The proposal is preliminary and non-binding, meaning there is no guarantee that it will lead to a definitive agreement or be consummated.
• The company explicitly states it does not undertake any obligation to provide updates or additional disclosures regarding the transaction, except as required by applicable law, which could lead to limited transparency for investors.

Risks

• There is no assurance that the company will pursue this transaction or any other strategic outcome.
• There is no assurance that a proposed transaction will be approved or consummated.
• No agreement, arrangement, or understanding between FONAR and the Proposed Acquisition Group will be created unless definitive documentation is executed and delivered by the appropriate parties.
• The company does not undertake any obligation to provide updates or additional disclosures to reflect subsequent events, new information, or future circumstances, except as required under applicable law, which may leave investors with incomplete information.

Future Outlook

The company's future outlook is uncertain regarding the proposed take-private transaction, as it is non-binding and subject to review by a special committee, with no assurance of approval or consummation. The company does not commit to providing further updates unless legally required.

Management Comments

• The Board has established a special committee consisting of independent and disinterested directors of the Board, who will carefully review the proposal to determine the course of action that is in the best interests of The Company and all shareholders.
• No action is required by FONAR shareholders at this time.
• FONAR cautions its shareholders and others considering trading in FONARs securities that FONAR has only recently received the proposal letter and has not had an opportunity to carefully review and evaluate the proposal or make any decision with respect to FONARs response to the proposal.
• The proposal constitutes only an indication of interest by the Proposed Acquisition Group and does not constitute a binding commitment.
• There can be no assurance that the Company will pursue this transaction or other strategic outcome, or that a proposed transaction will be approved or consummated.
• No agreement, arrangement or understanding between FONAR and the Proposed Acquisition Group relating to any proposed transaction will be created unless definitive documentation is executed and delivered by the appropriate parties.
• FONAR does not undertake any obligation to provide any updates with respect to this or any other transaction, or to provide any additional disclosures to reflect subsequent events, new information or future circumstances, except as required under applicable law.

Industry Context

FONAR operates in the medical imaging industry, specifically specializing in MRI technology. As 'The Inventor of MR Scanning,' it holds a historical position in the industry. Its signature UPRIGHT Multi-Position MRI addresses a niche by allowing weight-bearing scans, differentiating it from conventional lie-down scanners. The development of new technology for visualizing and quantifying cerebral hydraulics indicates ongoing innovation in a competitive and evolving healthcare technology sector. The take-private proposal, if successful, would remove a long-standing public company from the market, potentially consolidating ownership and strategic direction away from public scrutiny.

Comparison to Industry Standards

• FONAR's UPRIGHT Multi-Position MRI offers a unique capability for weight-bearing scans, which differentiates it from standard MRI manufacturers like Siemens Healthineers, GE Healthcare, and Philips, whose primary offerings are conventional lie-down scanners.
• The company's claim of a 'near-zero patient claustrophobic rejection rate' for its UPRIGHT MRI suggests a patient-friendly design that could be a competitive advantage compared to enclosed, tube-like MRI systems common across the industry.
• FONAR's new works-in-progress technology for visualizing and quantifying cerebral hydraulics of the central nervous system represents an innovative area of research, potentially expanding diagnostic capabilities beyond standard anatomical imaging offered by competitors.
• The company's primary income from its diagnostic imaging management subsidiary, Health Management Company of America (HMCA), indicates a business model that combines equipment manufacturing with service provision, a common strategy among larger medical device companies but perhaps less common for a specialized MRI manufacturer of FONAR's size.

Corporate Governance

Related Party Transactions

• The proposal is led by Timothy Damadian, the company's Chief Executive Officer, and includes certain members of the management team and Board of Directors, indicating a related-party transaction.

Stakeholder Impact

• Shareholders: Potential for a premium acquisition price, but also risk of the non-binding proposal not materializing, leading to uncertainty and potential share price volatility.
• Management/Board: Certain members are part of the Proposed Acquisition Group, indicating a potential change in ownership and control structure.
• Employees: No direct impact mentioned, but a take-private transaction could lead to future operational or structural changes.
• Customers/Suppliers: No immediate direct impact mentioned, but a change in ownership could influence future business relationships or strategic direction.

Next Steps

• The special committee of independent and disinterested directors will carefully review the proposal.
• The special committee will determine the course of action that is in the best interests of the company and all shareholders.
• Potential execution and delivery of definitive documentation if the transaction proceeds.

Key Dates

Recommendation

Keywords

FONAR Corporation, take-private proposal, management buyout, MRI, medical imaging, NASDAQ-FONR, special committee, shareholder value, corporate governance, healthcare technology